PEPCLUB.me

Mitochondrial HealthAnti-AgingCardiovascular HealthPerformance & EnergyArticlePremium

SS-31

10mg Vial

27 July 2026Updated 29 August 2026

SS-31

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for SS-31.

Create free account Member login

Full range of benefits for SS-31

Targets cardiolipin to stabilize the inner mitochondrial membrane

Reduces mitochondrial reactive oxygen species (ROS) production

Preserves mitochondrial membrane potential and integrity

Improves cellular ATP production in dysfunctional mitochondria

Decreases cytochrome c release and mitochondrial-mediated apoptosis

Mitigates ischemia–reperfusion injury in cardiac and renal models

Shown to improve cardiac function in some preclinical and clinical studies

Enhances skeletal muscle mitochondrial function and exercise tolerance

May reduce inflammation secondary to mitochondrial damage

Exhibits neuroprotective effects in models of neurodegeneration

May support renal mitochondrial health in acute kidney injury models

May enhance mitophagy and clearance of damaged mitochondria

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 17 known interactions

Synergistic(4)Compatible(4)Monitor(5)Avoid(4)

Generally well-tolerated alongside this peptide

ACE inhibitors (e.g., ramipril)

ACE inhibitors used for cardiovascular indications have no known direct pharmacologic antagonism with SS-31 and are generally compatible under usual clinical care.

Beta-blockers (e.g., metoprolol)

Beta-blockers have neutral co-administration profiles with SS-31 and can be continued without specific SS-31 dose adjustment in most patients.

Acetaminophen (paracetamol)

Acetaminophen does not have a documented interaction with SS-31 and is considered compatible for analgesia/antipyresis.

Aspirin (low-dose antiplatelet)

Low-dose aspirin for antiplatelet therapy has no established adverse interaction with SS-31 and is typically compatible.

All interaction categories

Synergistic (4)

Coenzyme Q10 (ubiquinone): CoQ10 supports electron transport and antioxidant capacity and may complement SS-31's mitochondrial membrane and ROS-stabilising effects to enhance bioenergetics.
Mitochondria-targeted antioxidants (e.g., MitoQ): Targeted antioxidants address mitochondrial oxidative stress through complementary mechanisms and can synergise with SS-31's cardiolipin-stabilising and ROS-modulating actions.
Nicotinamide riboside / other NAD+ precursors: NAD+ precursors boost NAD-dependent metabolic and repair pathways and can augment SS-31-mediated improvements in mitochondrial function.
L-carnitine: L-carnitine facilitates mitochondrial fatty acid transport and may work additively with SS-31 to improve mitochondrial energy metabolism.

Compatible (4)

ACE inhibitors (e.g., ramipril): ACE inhibitors used for cardiovascular indications have no known direct pharmacologic antagonism with SS-31 and are generally compatible under usual clinical care.
Beta-blockers (e.g., metoprolol): Beta-blockers have neutral co-administration profiles with SS-31 and can be continued without specific SS-31 dose adjustment in most patients.
Acetaminophen (paracetamol): Acetaminophen does not have a documented interaction with SS-31 and is considered compatible for analgesia/antipyresis.
Aspirin (low-dose antiplatelet): Low-dose aspirin for antiplatelet therapy has no established adverse interaction with SS-31 and is typically compatible.

Monitor (5)

Statins (e.g., atorvastatin): Because statins can affect mitochondrial function and increase myopathy risk, monitor for myalgias and check creatine kinase when combined with SS-31.
Valproate: Valproate is associated with mitochondrial toxicity in susceptible patients, so liver function and neurological status should be monitored if used concomitantly with SS-31.
Aminoglycoside antibiotics (e.g., gentamicin): Given aminoglycoside nephrotoxicity/ototoxicity and potential additive mitochondrial stress, monitor renal function and hearing during co-administration with SS-31.
Metformin: Metformin impacts mitochondrial complex I activity and carries rare lactic acidosis risk, so monitor renal function and metabolic status when co-prescribed with SS-31.
Insulin and insulin secretagogues: Improvements in cellular bioenergetics could alter glycaemic control, so monitor blood glucose and adjust antidiabetic dosing as clinically indicated.

Avoid (4)

Linezolid: Linezolid has been associated with mitochondrial toxicity and serotonin-related effects, so concurrent use with SS-31 warrants careful risk–benefit assessment and monitoring.
Other investigational or experimental mitochondrial modulators: Combining investigational mitochondrial-targeted agents with SS-31 may have unpredictable additive or opposing effects and requires specialist review and protocolised monitoring.
Pregnancy and breastfeeding: Safety data for SS-31 in pregnancy and lactation are limited, so use during pregnancy or breastfeeding should be avoided or carefully evaluated by a specialist.
Concurrent drugs with known mitochondrial toxicity (e.g., certain antiretrovirals, chloramphenicol): Drugs known to impair mitochondrial function may increase the risk of adverse effects when combined with SS-31 and should be used with caution and close monitoring.